Adient ADNT R&D
R&D at other companies
Other financials
Where this comes from
Reported directly by Adient in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Adient’s 10-K, filed November 18, 2025.
- Filed
- Nov 18, 2025
- Fiscal year
- FY2025
- Accession
- 0001670541-25-000152
Expenditures for research activities relating to product development and improvement (other than those expenditures that are contractually guaranteed for reimbursement from the customer) are charged against income as incurred and included within selling, general and administrative expenses in the consolidated statements of income (loss). Such expenditures for the years ended September 30, 2025, 2024 and 2023 were $387 million, $372 million and $362 million, respectively. A portion of these costs associated with these activities are reimbursed by customers in the amounts of $288 million, $280 million and $250 million for the fiscal years ended September 30, 2025, 2024 and 2023, respectively.
Item 8. Financial Statements and Supplementary Data
FAQ
- What is Adient's R&D?
- Adient (ADNT) reported R&D of $96.75M in Q3 2025.
- How has Adient's R&D changed year-over-year?
- Adient's R&D increased by 4.0% year-over-year, from $93M to $96.75M.
- What is the long-term trend for Adient's R&D?
- Over 4 years (2021 to 2025), Adient's R&D has grown at a 5.2% compound annual growth rate (CAGR), from $316M to $387M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Adient's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
